Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

MDT-AP-0734

Med · Medulloblastoma

dabab85b-e412-56cd-b683-50ad45d880b4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
Med
cancer_type_detailed
subtype
Medulloblastoma
cancer_type
Med
subtype
Medulloblastoma
overall_survival_months
120
os_event
false
age_years
12
sex
M
new_clusters
C6
umap1_2d
3.92423713
umap2_2d
6.650686401
umap1_3d
3.072664123
umap2_3d
-0.634126588
umap3_3d
-4.561271563
dataset
Med-Taylor

GSVA pathway preview (0 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

No GSVA scores available for this sample.

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-0153
medullo-epn-umap@date-based
MedMedulloblastoma0.946
2MDT-AP-3267
medullo-epn-umap@date-based
MedMedulloblastoma0.917
3MDT-AP-0830
medullo-epn-umap@date-based
MedMedulloblastoma0.916
4MDT-AP-0393
medullo-epn-umap@date-based
MedMedulloblastoma0.902
5MDT-AP-0838
medullo-epn-umap@date-based
MedMedulloblastoma0.896
6MDT-AP-0808
medullo-epn-umap@date-based
MedMedulloblastoma0.888
7MDT-AP-0376
medullo-epn-umap@date-based
MedMedulloblastoma0.888
8MDT-AP-0364
medullo-epn-umap@date-based
MedMedulloblastoma0.879
9BS_A87NPZAP
medullo-epn-umap@date-based
MedMedulloblastoma0.867
10MDT-AP-0373
medullo-epn-umap@date-based
MedMedulloblastoma0.864

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 5 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.150Remibrutinib— uncovered
HEME_METABOLISM0.110Temsirolimus— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered
HEDGEHOG_SIGNALING0.070Inavolisib— uncovered
APICAL_SURFACE0.030Temsirolimus— uncovered